- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07673107
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.
AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.
Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.
The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3S 1N2
- Rekruttering
- True North Clinical Research /ID# 277130
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Rekruttering
- Centre de Recherche St-Louis /ID# 277106
-
Pointe-Claire, Quebec, Canada, H9R 4Y2
- Rekruttering
- Genge Partners /ID# 277096
-
-
-
-
California
-
Carlsbad, California, Forente stater, 92011
- Rekruttering
- The Neurology Center of Southern California - Carlsbad /ID# 278194
-
Fresno, California, Forente stater, 93710
- Rekruttering
- Neuro Pain Research Center /ID# 277899
-
Fullerton, California, Forente stater, 92835
- Rekruttering
- Neurology Center Of North Orange County /ID# 278490
-
-
Connecticut
-
Stamford, Connecticut, Forente stater, 06905
- Rekruttering
- New England Institute for Clinical Research /ID# 277315
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33486
- Rekruttering
- Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
-
Orlando, Florida, Forente stater, 32803-1839
- Rekruttering
- Charter Research - Winter Park /ID# 277875
-
Pensacola, Florida, Forente stater, 32504-8649
- Rekruttering
- Emerald Coast Neurology /ID# 277898
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66211-1358
- Rekruttering
- Kansas Institute of Research /ID# 277068
-
-
New York
-
Amherst, New York, Forente stater, 14226
- Rekruttering
- Dent Neurologic Institute - Amherst /ID# 277242
-
Commack, New York, Forente stater, 11725
- Rekruttering
- True North Neurology /ID# 278118
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27103
- Rekruttering
- Neurology - Triad /ID# 277088
-
-
Ohio
-
New Albany, Ohio, Forente stater, 43054
- Rekruttering
- Mount Carmel Health System /ID# 278234
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38157
- Rekruttering
- Veracity Neuroscience /ID# 277081
-
-
Texas
-
Dallas, Texas, Forente stater, 75206-5202
- Rekruttering
- Texas Neurology /ID# 277067
-
Frisco, Texas, Forente stater, 75035
- Rekruttering
- Lone Star Neurology /ID# 278266
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital /ID# 277326
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- Rekruttering
- University of Virginia /ID# 278191
-
-
Washington
-
Spokane, Washington, Forente stater, 99202
- Rekruttering
- Inland Northwest Research /ID# 277077
-
-
Wisconsin
-
Greenfield, Wisconsin, Forente stater, 53228
- Rekruttering
- Center For Neurological Disorders /ID# 277048
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Minimum body weight of 50 kg (110 pounds) at Screening.
-
Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows:
- Bilateral postural tremor with or without kinetic tremor, involving hands and forearms
- Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor
- Bilateral tremor may or may not be asymmetric
- Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate.
Exclusion Criteria:
- History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders.
- History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its excipients and/or other botulinum toxins.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: AGN-151607-DP
Participants will receive AGN-151607-DP. |
Intramuscular Injection |
|
Placebo komparator: Placebo for AGN-151607-DP
Participants will receive Placebo for AGN-151607-DP. |
Intramuscular Injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)
Tidsramme: 72 weeks
|
TETRAS assesses participants' ability to function. Items are rated on a 5-category response scale from 0 (no tremor) to 4 (severe tremor). |
72 weeks
|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: 72 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
72 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in The Essential Tremor Rating Assessment Scale - Upper Limb (TETRAS-UL)
Tidsramme: 72 weeks
|
TETRAS Upper Limb (UL) Scale is an item of the TETRAS performance subscale that is designed to assess upper limb tremor. Items are scored from 0 to 4, with 0 indicating no tremor and 4 indicating a severe tremor. |
72 weeks
|
|
Change From Baseline in Clinical Global Impression of Severity (CGIS)
Tidsramme: 72 weeks
|
CGI-S is a single item used to measure the clinician's impression of the current severity of the patient's essential tremor. The measure uses a 5-point rating scale with scores ranging none to very severe. |
72 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: ABBVIE INC., AbbVie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- M25-850
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Tilgangskriterier for IPD-deling
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .